Delcath Systems Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good day, and thanks for joining us to have a conversation with Gerard Michel, CEO of Delcath. Delcath is an interventional oncology company that's developing in minimally invasive percutaneous perfusion technology to treat primary and secondary tumors of the liver. The company, under Gerard, has completed analysis of the Phase 3 study and is expected to file the NDA in the fourth quarter and recently have started commercializing the product in EU with its own sales force.
So to talk about the company's strategy for '22 and beyond, I welcome Gerard to this fireside chat with me. Gerard, glad to see you.
RK, (inaudible) Thank you for having me.
And appreciate you accepting our invitation to join us. So Gerard, just to set up the stage for the audience here and help us familiarize with Delcath's business strategy, if you can start.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
